Research & Literature

Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.

DeZern AE, Brodsky RA

Hematology/oncology clinics of North America 2015; (29(3)):479-94.

[Paroxysmal nocturnal hemoglobinuria: An unknown cause of thrombosis?].

Doutrelon C, Skopinski S, Boulon C, et al.

Journal des maladies vasculaires 2015; (40(6)):384-90.

Distinct subgroups of paroxysmal nocturnal hemoglobinuria (PNH) with cytopenia: results from South Korean National PNH Registry.

Kim JS, Jang JH, Yoon SS, et al.

Annals of hematology 2016; (95(1)):125-133 doi:10.1007/s00277-015-2511-z.

Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Nakayama H, Usuki K, Echizen H, et al.

Biological & pharmaceutical bulletin 2016; (39(2)):285-8 doi:10.1248/bpb.b15-00703.

Cerebral venous thrombosis presenting with intracerebral hemorrhage in a patient with paroxysmal nocturnal hemoglobinuria.

Shrestha GS, Poudyal BS, Sedain G, et al.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 2016; (20(2)):117-9 doi:10.4103/0972-5229.175948.

Exposure of Stored Packed Erythrocytes to Nitric Oxide Prevents Transfusion-associated Pulmonary Hypertension.

Muenster S, Beloiartsev A, Yu B, et al.

Anesthesiology 2016; (125(5)):952-963 doi:10.1097/ALN.0000000000001294.

Pathogenesis of paroxysmal nocturnal hemoglobinuria.

Murakami Y

[Rinsho ketsueki] The Japanese journal of clinical hematology 2016; (57(10)):1900-1907 doi:10.11406/rinketsu.57.1900.

Paroxysmal Nocturnal Hemoglobinuria: From Bench to Bed.

Mohammed AA, El-Tanni H, Atiah TA, et al.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2016; (32(4)):383-391 doi:10.1007/s12288-016-0654-2.

Eculizumab: another breakthrough.

Brodsky RA

Blood 2017; (129(8)):922-923 doi:10.1182/blood-2017-01-760496.

Paediatric meningococcaemia in northwestern Ontario, Canada: a case for publicly funded meningococcal B vaccination.

Eton V, Tsang RS, Ulanova M

JMM case reports 2016; (3(1)):e005017 doi:10.1099/jmmcr.0.005017.

Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status.

Yenerel MN, Muus P, Wilson A, Szer J

Blood cells, molecules & diseases 2017; (65()):29-34 doi:10.1016/j.bcmd.2017.03.013.

Molecular genetics, biochemistry, and biology of PNH.

Kinoshita T

[Rinsho ketsueki] The Japanese journal of clinical hematology 2017; (58(4)):353-362 doi:10.11406/rinketsu.58.353.

Persisting hyperbilirubinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with eculizumab: The role of hepatocanalicular transporter variants.

Alashkar F, Weber SN, Vance C, et al.

European journal of haematology 2017; (99(4)):350-356 doi:10.1111/ejh.12927.

High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.

McNamara LA, Topaz N, Wang X, et al.

MMWR. Morbidity and mortality weekly report 2017; (66(27)):734-737 doi:10.15585/mmwr.mm6627e1.

Origins of myelodysplastic syndromes after aplastic anemia.

Negoro E, Nagata Y, Clemente MJ, et al.

Blood 2017; (130(17)):1953-1957 doi:10.1182/blood-2017-02-767731.

Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort.

Choi CW, Jang JH, Kim JS, et al.

Blood research 2017; (52(3)):207-211 doi:10.5045/br.2017.52.3.207.

Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis.

Pagliuca S, Risitano AM, De Fontbrune FS, et al.

Bone marrow transplantation 2018; (53(1)):105-107 doi:10.1038/bmt.2017.220.

Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers.

Vallet N, de Fontbrune FS, Loschi M, et al.

Haematologica 2018; (103(3)):e103-e105 doi:10.3324/haematol.2017.182360.

Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan.

Ueda Y, Obara N, Yonemura Y, et al.

International journal of hematology 2018; (107(6)):656-665 doi:10.1007/s12185-018-2409-3.

Reply letter to "Fatal meningococcemia due to Neisseria meningitidis serogroup Y in a vaccinated child receiving eculizumab".

Dretler AW, Rouphael NG, Stephens DS

Human vaccines & immunotherapeutics 2018; (14(11)):2803-2804 doi:10.1080/21645515.2018.1491247.

Bone Marrow as a Source of Cells for Paroxysmal Nocturnal Hemoglobinuria Detection.

Dulau-Florea AE, Young NS, Maric I, et al.

American journal of clinical pathology 2018; (150(3)):273-282 doi:10.1093/ajcp/aqy053.

Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab.

Nolfi-Donegan D, Konar M, Vianzon V, et al.

Emerging infectious diseases 2018; (24(8)) doi:10.3201/eid2408.180228.

C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.

Notaro R, Sica M

Seminars in hematology 2018; (55(3)):130-135 doi:10.1053/j.seminhematol.2018.05.014.

Congenital Defects in the Expression of the Glycosylphosphatidylinositol-Anchored Complement Regulatory Proteins CD59 and Decay-Accelerating Factor.

Kinoshita T

Seminars in hematology 2018; (55(3)):136-140 doi:10.1053/j.seminhematol.2018.04.004.

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, de Witte T, et al.

Blood advances 2018; (2(14)):1765-1772 doi:10.1182/bloodadvances.2018019414.

[Paroxysmal nocturnal hemoglobinuria and thrombosis in the era of eculizumab].

Nishimura JI

[Rinsho ketsueki] The Japanese journal of clinical hematology 2018; (59(8)):1042-1047 doi:10.11406/rinketsu.59.1042.

Paroxysmal nocturnal hemoglobinuria.

Čermák J

Vnitrni lekarstvi 2018; (64(5)):508-513.

Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria.

Griffin M, Hillmen P, Munir T, et al.

Haematologica 2019; (104(3)):e94-e96 doi:10.3324/haematol.2018.198846.

Comparison of High Sensitivity and Conventional Flow Cytometry for Diagnosing Overt Paroxysmal Nocturnal Hemoglobinuria and Detecting Minor Paroxysmal Nocturnal Hemoglobinuria Clones.

Park SH, Jeong J, Lee SH, et al.

Annals of laboratory medicine 2019; (39(2)):150-157 doi:10.3343/alm.2019.39.2.150.

Paroxysmal nocturnal hemoglobinuria testing in patients with myelodysplastic syndrome in clinical practice-frequency and indications.

Wong SA, Dalal BI, Leitch HA

Current oncology (Toronto, Ont.) 2018; (25(5)):e391-e397 doi:10.3747/co.25.4018.

Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria.

Escalante CP, Chisolm S, Song J, et al.

Cancer medicine 2019; (8(2)):543-553 doi:10.1002/cam4.1953.

Abdominal pain in combination with an unexplained hemolytic anemia are crucial signs to test for paroxysmal nocturnal hemoglobinuria: A case report.

Elias NS, Riedl J, Stouten K, et al.

Clinical case reports 2019; (7(1)):175-179 doi:10.1002/ccr3.1771.

[Comparison of haploidentical hematopoietic stem cell transplantation and matched-sibling donor transplantation for the treatment of paroxysmal nocturnal hemoglobinuria].

Liu LM, Zhou HF, Wang QY, et al.

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2019; (40(4)):306-311 doi:10.3760/cma.j.issn.0253-2727.2019.04.008.

Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.

Harder MJ, Höchsmann B, Dopler A, et al.

Frontiers in immunology 2019; (10()):1639 doi:10.3389/fimmu.2019.01639.

Mechanisms of haemolysis-induced kidney injury.

Van Avondt K, Nur E, Zeerleder S

Nature reviews. Nephrology 2019; (15(11)):671-692 doi:10.1038/s41581-019-0181-0.

Evolution patterns of paroxysmal nocturnal hemoglobinuria clone and clinical implications in acquired bone marrow failure.

Lian Y, Shi J, Nie N, et al.

Experimental hematology 2019; (77()):41-50 doi:10.1016/j.exphem.2019.08.005.

Analysis of clinical characteristics of 92 patients with paroxysmal nocturnal hemoglobinuria: A single institution experience in China.

Fu R, Li L, Li L, et al.

Journal of clinical laboratory analysis 2020; (34(1)):e23008 doi:10.1002/jcla.23008.

Diagnosis of paroxysmal nocturnal hemoglobinuria with flowcytometry panels including CD157: Data from the real world.

Zhang Y, Ding J, Gu H, et al.

Cytometry. Part B, Clinical cytometry 2020; (98(2)):193-202 doi:10.1002/cyto.b.21847.

CD71 improves delineation of PNH type III, PNH type II, and normal immature RBCS in patients with paroxysmal nocturnal hemoglobinuria.

Sutherland DR, Richards SJ, Ortiz F, et al.

Cytometry. Part B, Clinical cytometry 2020; (98(2)):179-192 doi:10.1002/cyto.b.21853.

Paroxysmal Nocturnal Hemoglobinuria: An Underestimated Cause of Pediatric Thromboembolism.

Griesser C, Myskiw M, Streif W

TH open : companion journal to thrombosis and haemostasis 2020; (4(1)):e36-e39 doi:10.1055/s-0040-1702155.

Neisseria meningitidis Induced Fatal Waterhouse-Friderichsen Syndrome in a Patient Presenting With Disseminated Intravascular Coagulation and Multiple Organ Failure.

Wu MY, Chen CS, Tsay CY, et al.

Brain sciences 2020; (10(3)) doi:10.3390/brainsci10030171.

Allogeneic Hematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria: Multicenter Analysis by the Polish Adult Leukemia Group.

Markiewicz M, Drozd-Sokolowska J, Biecek P, et al.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2020; (26(10)):1833-1839 doi:10.1016/j.bbmt.2020.05.024.

Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria.

Cançado RD, Araújo ADS, Sandes AF, et al.

Hematology, transfusion and cell therapy 2021; (43(3)):341-348 doi:10.1016/j.htct.2020.06.006.

A Rare Case of Paroxysmal Nocturnal Hemoglobinuria With Bilateral Renal Vein Thrombosis.

Lodhi OUH, Sohail S, Hassan D

Cureus 2020; (12(6)):e8806 doi:10.7759/cureus.8806.

Small hepatic veins Budd-Chiari syndrome and paroxysmal nocturnal hemoglobinuria - The association of two rare entities: a case report.

Gioia S, De Santis E, Cerbelli B, et al.

Pathologica 2020; (112(2)):102-104 doi:10.32074/1591-951X-4-20.

Reduced red blood cell surface level of Factor H as a mechanism underlying paroxysmal nocturnal hemoglobinuria.

Zhang L, Chen JY, Kerr C, et al.

Leukemia 2021; (35(4)):1176-1187 doi:10.1038/s41375-020-1008-5.

Utility of FLAER and CD157 in a five-color single-tube high sensitivity assay, for diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH)-A standalone flow cytometry laboratory experience.

Seth N, Mahajan V, Kedia S, et al.

International journal of laboratory hematology 2021; (43(2)):259-265 doi:10.1111/ijlh.13366.

Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.

Bozio CH, Isenhour C, McNamara LA

PloS one 2020; (15(11)):e0241989 doi:10.1371/journal.pone.0241989.

The predictive value of pre-treatment paroxysmal nocturnal hemoglobinuria clone on response to immunosuppressive therapy in patients with aplastic anemia: a meta-analysis.

Wang B, He B, Zhu YD, Wu W

Hematology (Amsterdam, Netherlands) 2020; (25(1)):464-472 doi:10.1080/16078454.2020.1848083.

Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology.

Bektas M, Copley-Merriman C, Khan S, et al.

Journal of managed care & specialty pharmacy 2020; (26(12-b Suppl)):S3-S8 doi:10.18553/jmcp.2020.26.12-b.s3.

Limb-clasping, cognitive deficit and increased vulnerability to kainic acid-induced seizures in neuronal glycosylphosphatidylinositol deficiency mouse models.

Kandasamy LC, Tsukamoto M, Banov V, et al.

Human molecular genetics 2021; (30(9)):758-770 doi:10.1093/hmg/ddab052.

Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Aplastic Anemia: A Multicenter Turkish Experience

Yılmaz F, Soyer N, Cengiz Seval G, et al.

Turkish journal of haematology : official journal of Turkish Society of Haematology 2021; (38(3)):195-203 doi:10.4274/tjh.galenos.2021.2021.0105.

A Rare and Misdiagnosed Entity Paroxysmal Nocturnal Hemoglobinuria: A Case Report.

Pokhrel B, Gautam S, Khanal S, et al.

Cureus 2021; (13(5)):e14902 doi:10.7759/cureus.14902.

Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab.

Kulasekararaj AG, Risitano AM, Maciejewski JP, et al.

Blood 2021; (138(20)):1928-1938 doi:10.1182/blood.2021011388.

Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.

Bhak RH, Mody-Patel N, Baver SB, et al.

Current medical research and opinion 2021; (37(11)):1913-1923 doi:10.1080/03007995.2021.1971182.

A novel patient-reported outcome instrument assessing the symptoms of paroxysmal nocturnal hemoglobinuria, the PNH-SQ.

Daly RP, Jalbert JJ, Keith S, et al.

Journal of patient-reported outcomes 2021; (5(1)):102 doi:10.1186/s41687-021-00376-0.

The Role of T Lymphocytes in the Pathogenesis of Paroxysmal Nocturnal Hemoglobinuria.

Li C, Dong X, Wang H, Shao Z

Frontiers in immunology 2021; (12()):777649 doi:10.3389/fimmu.2021.777649.

Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan.

Ikezoe T, Noji H, Ueda Y, et al.

International journal of hematology 2022; (115(4)):470-480 doi:10.1007/s12185-022-03287-y.

Literature Review of Fatigue Scales and Association with Clinically Meaningful Improvements in Outcomes Among Patients With and Without Paroxysmal Nocturnal Hemoglobinuria.

Krishnan S, Sarda S, Kunzweiler C, et al.

Advances in therapy 2022; (39(5)):1959-1975 doi:10.1007/s12325-022-02111-7.

Significance of paroxysmal nocturnal hemoglobinuria clone in immunosuppressive therapy for children with severe aplastic anemia.

Li J, Zong SY, Yin ZX, et al.

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2022; (24(3)):303-308 doi:10.7499/j.issn.1008-8830.2110109.

Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real-world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry.

Höchsmann B, de Fontbrune FS, Lee JW, et al.

European journal of haematology 2022; (109(3)):197-204 doi:10.1111/ejh.13773.

Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15.

Tsuji N, Hosokawa K, Urushihara R, et al.

Leukemia 2022; (36(6)):1666-1675 doi:10.1038/s41375-022-01549-6.

Aplastic anemia: Pathophysiology.

Giudice V, Selleri C

Seminars in hematology 2022; (59(1)):13-20 doi:10.1053/j.seminhematol.2021.12.002.

Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress.

Peffault de Latour R, Hosokawa K, Risitano AM

Seminars in hematology 2022; (59(1)):38-46 doi:10.1053/j.seminhematol.2022.01.001.

Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: A systematic review on efficacy and safety.

Shah S, Chamlagain R, Musalman ZH, et al.

Research and practice in thrombosis and haemostasis 2022; (6(5)):e12781 doi:10.1002/rth2.12781.

Somatic mutations and clonal expansions in paroxysmal nocturnal hemoglobinuria.

Hosokawa K, Nakao S

Seminars in hematology 2022; (59(3)):143-149 doi:10.1053/j.seminhematol.2022.08.004.

Immunophenotypic assessment of PNH clones in major and minor cell lineages in the peripheral blood of patients with paroxysmal nocturnal hemoglobinuria.

Richards SJ, Dickinson AJ, Newton DJ, Hillmen P

Cytometry. Part B, Clinical cytometry 2022; (102(6)):487-497 doi:10.1002/cyto.b.22094.

Paroxysmal nocturnal hemoglobinuria: Where are we going.

Kulasekararaj AG, Lazana I

American journal of hematology 2023; (98 Suppl 4()):S33-S43 doi:10.1002/ajh.26882.

Meningococcemia in an 11 Months Old Infant.

Shrestha R, Karki S, Khadka M, et al.

Case reports in infectious diseases 2023; (2023()):8951318 doi:10.1155/2023/8951318.

Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.

Bodó I, Amine I, Boban A, et al.

Advances in therapy 2023; (40(6)):2752-2772 doi:10.1007/s12325-023-02510-4.

Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case-control study in the International PNH Registry.

Höchsmann B, Peffault de Latour R, Hill A, et al.

Annals of hematology 2023; (102(11)):2979-2988 doi:10.1007/s00277-023-05402-3.

Paroxysmal Nocturnal Hemoglobinuria: Biology and Treatment.

Bravo-Perez C, Guarnera L, Williams ND, Visconte V

Medicina (Kaunas, Lithuania) 2023; (59(9)) doi:10.3390/medicina59091612.

Candida krusei pneumonia in graft-versus-host disease after allogeneic hematopoietic stem cell transplant for paroxysmal nocturnal hemoglobinuria: a case report.

Zoowa R, Shah R, Pradhan D, et al.

Annals of medicine and surgery (2012) 2023; (85(12)):6168-6172 doi:10.1097/MS9.0000000000001374.

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria.

Kelly RJ, Holt M, Vidler J, et al.

Blood 2024; (143(12)):1157-1166 doi:10.1182/blood.2023021762.

Meningococcal Disease in Persons With HIV Reported Through Active Surveillance in the United States, 2009-2019.

Rudmann KC, Cooper G, Marjuki H, et al.

Open forum infectious diseases 2024; (11(1)):ofad696 doi:10.1093/ofid/ofad696.

[Expert consensus on clonal screening and monitoring of complement inhibitor therapy in paroxysmal nocturnal hemoglobinuria (2024)].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2024; (45(2)):109-114 doi:10.3760/cma.j.cn121090-20230927-00145.

Advances in research on renal injury in paroxysmal nocturnal hemoglobinuria.

Li L, Fu R

Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2024; (72(8)):828-833 doi:10.1177/10815589241254046.

[Analysis and summary of clinical characteristics of 289 patients with paroxysmal nocturnal hemoglobinuria in Zhejiang Province].

Xu GX, Jin WM, Ye BD, et al.

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2024; (45(6)):549-555 doi:10.3760/cma.j.cn121090-20240127-00041.

Epidemiological estimates of paroxysmal nocturnal hemoglobinuria in Bulgaria.

Beleva E

Intractable & rare diseases research 2024; (13(3)):190-194 doi:10.5582/irdr.2024.01016.

Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors.

Hillmen P, Horneff R, Yeh M, et al.

International journal of molecular sciences 2024; (25(17)) doi:10.3390/ijms25179477.

Deciphering Paroxysmal Nocturnal Hemoglobinuria: An Unusual Paradigm of Hemolytic Anemia.

Athota S, Gopalan S, Arthur P, et al.

Cureus 2024; (16(8)):e67194 doi:10.7759/cureus.67194.

[Paroxysmal nocturnal hemoglobinuria during pregnancy: a case report and literature review].

Wang W, Wang XQ

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2024; (45(9)):861-863 doi:10.3760/cma.j.cn121090-20240411-00137.

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Crass RL, Smith B, Adriaens S, et al.

Drugs in R&D 2024; (24(4)):563-573 doi:10.1007/s40268-024-00500-7.

A Cluster of Meningococcal Serogroup W135 Infections: A Case Series.

Al-Anbagi U, Al Maslamani M, Al-Khal A, et al.

Cureus 2025; (17(3)):e80747 doi:10.7759/cureus.80747.

The incidence of paroxysmal nocturnal hemoglobinuria cell clones in the Nordic countries.

Pedersen TH, Tjønnfjord E, Korkama ES, et al.

Annals of hematology 2025; (104(8)):4277-4283 doi:10.1007/s00277-025-06450-7.

Immunogenicity and safety of meningococcal vaccines, MenACWY-CRM and 4CMenB, in groups at increased risk for meningococcal disease.

Bobde S, Bhusal C, Cosgrove CA, Sohn WY

Expert review of vaccines 2025; (24(1)):656-667 doi:10.1080/14760584.2025.2536079.

Paroxysmal nocturnal hemoglobinuria revealed by atypical thromboses: A case of cerebral, hepatic, and portal vein involvement leading to cirrhosis.

Malghi M, Zouaoui M, Bamaarouf I, et al.

Radiology case reports 2025; (20(12)):6178-6182 doi:10.1016/j.radcr.2025.09.004.

Paroxysmal Nocturnal Hemoglobinuria.

Godby RC, Shah S

Mayo Clinic proceedings 2025; (100(12)):2206-2227 doi:10.1016/j.mayocp.2025.07.029.

Disease-modifying treatments in paroxysmal nocturnal hemoglobinuria: a systematic review of economic evaluations.

Moradi S, Khajeamiri Y, Zandi S, et al.

Cost effectiveness and resource allocation : C/E 2025; (24(1)):18 doi:10.1186/s12962-025-00702-z.

Clonal expansion mechanisms in paroxysmal nocturnal hemoglobinuria.

Kinoshita T

International journal of hematology 2026; doi:10.1007/s12185-026-04167-5.

Paroxysmal Nocturnal Hemoglobinuria in a Young Adult Woman: A Representative Case of Recurrent Intravascular Hemolysis.

Pera R, Lagarteira J, Sá S, et al.

Cureus 2026; (18(1)):e100884 doi:10.7759/cureus.100884.

Immunological links between aplastic anemia and paroxysmal nocturnal hemoglobinuria.

Hosokawa K

International journal of hematology 2026; doi:10.1007/s12185-026-04236-9.

Thromboembolic Events in Indian Patients with Paroxysmal Nocturnal Hemoglobinuria: A Single Centre Experience.

Datta G, Verma SP, Raghuveer P, et al.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2026; (42(4)):1270-1276 doi:10.1007/s12288-025-02141-5.